Antitumor activity of nintedanib (BIBF 1120), a triple angiokinase inhibitor, in combination with gemcitabine in experimental pancreatic cancer

被引：0
|
作者：
Awasthi, Niranjan [1 ]
Hinz, Stefan [2 ]
Brekken, Rolf A. [2 ]
Schwarz, Margaret A. [1 ]
Schwarz, Roderich E. [1 ]
机构：
[1] Indiana Univ Sch Med, South Bend, IN USA
[2] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA
来源：
CANCER RESEARCH | 2014年 / 74卷 / 19期
关键词：
D O I：
10.1158/1538-7445.AM2014-1025
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1025
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Antitumour activity of sunitinib in combination with gemcitabine in experimental pancreatic cancer
    Awasthi, Niranjan
    Schwarz, Margaret A.
    Schwarz, Roderich E.
    HPB, 2011, 13 (09) : 597 - 604
  • [32] Molecular evidence of increased antitumor activity of gemcitabine in combination with a Cdk inhibitor, P276 in pancreatic cancer
    Joshi, Kalpana S.
    Rathos, Maggie J.
    Joshi, Kavita
    Khanwalkar, Harshal
    Sharma, Somesh
    MOLECULAR CANCER THERAPEUTICS, 2009, 8 (12)
  • [33] Phase I Open-Label Study of Continuous Treatment with BIBF 1120, a Triple Angiokinase Inhibitor, and Pemetrexed in Pretreated Non-Small Cell Lung Cancer Patients
    Ellis, Peter M.
    Kaiser, Rolf
    Zhao, Yihua
    Stopfer, Peter
    Gyorffy, Steve
    Hanna, Nasser
    CLINICAL CANCER RESEARCH, 2010, 16 (10) : 2881 - 2889
  • [34] An open label randomized Phase II study of oral triple angiokinase inhibitor BIBF 1120 in Hormone Refractory Prostate Cancer (HRPC) patients who progressed after docetaxel
    Oudard, S.
    Chevreau, C.
    Flechon, A.
    Gunzer, K.
    Houede, N.
    Krakowski, I.
    de Mont-Serrat, H.
    Rouyrre, N.
    Kaiser, R.
    Droz, J. P.
    EJC SUPPLEMENTS, 2007, 5 (04): : 280 - 280
  • [35] A Phase II double-blind study to investigate efficacy and safety of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small cell lung cancer
    Reck, Martin
    Kaiser, Rolf
    Eschbach, Corinna
    Stefanie, Martin
    Love, James
    Staab, Alexander
    Freiwald, Matthias
    Bruno, Rene
    Stopfer, Peter
    Gatzemeier, Ulrich
    von Pawel, Joachim
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S707 - S707
  • [36] Effect of a novel oral chemotherapeutic agent containing a combination of trifluridine, tipiracil and the novel triple angiokinase inhibitor nintedanib, on human colorectal cancer xenografts
    Suzuki, Norihiko
    Nakagawa, Fumio
    Matsuoka, Kazuaki
    Takechi, Teiji
    ONCOLOGY REPORTS, 2016, 36 (06) : 3123 - 3130
  • [37] A phase II double-blind study to investigate efficacy and safety of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small cell lung cancer (NSCLC)
    Reck, M.
    Kaiser, R.
    Eschbach, C.
    Stefanic, M.
    Gaschler-Markefski, B.
    Gatzemeier, U.
    von Pawel, J.
    ONKOLOGIE, 2010, 33 : 286 - 286
  • [38] Phase II trial of triple-receptor tyrosine kinase receptor inhibitor nintedanib (BIBF 1120) in recurrent high-grade gliomas.
    Norden, Andrew David
    Schiff, David
    Ahluwalia, Manmeet Singh
    Lesser, Glenn Jay
    Nayak, Lakshmi
    Lee, Eudocia Quant
    Muzikansky, Alona
    Dietrich, Jorg
    Smith, Katrina H.
    Gaffey, Sarah C.
    McCluskey, Christine Sceppa
    Ligon, Keith L.
    Reardon, David A.
    Wen, Patrick Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [39] The Antitumor Activity of Sodium Selenite Alone and in Combination with Gemcitabine in Pancreatic Cancer: An In Vitro and In Vivo Study
    Doello, Kevin
    Mesas, Cristina
    Quinonero, Francisco
    Perazzoli, Gloria
    Cabeza, Laura
    Prados, Jose
    Melguizo, Consolacion
    Ortiz, Raul
    CANCERS, 2021, 13 (13)
  • [40] Antitumor activity of the novel HDAC inhibitor CUDC-101 combined with gemcitabine in pancreatic cancer
    Ji, Meiying
    Li, Zhenling
    Lin, Zhenhua
    Chen, Liyan
    AMERICAN JOURNAL OF CANCER RESEARCH, 2018, 8 (12): : 2402 - 2418
12345